Laird Harrison

home / authors / laird-harrison

Articles

COVID-19 implicated in conjunctivitis

COVID-19 implicated in conjunctivitis

Laird Harrison
May 15th 2020

Visual impairment high among Rohingya refugees

Visual impairment high among Rohingya refugees

Laird Harrison
May 7th 2020

Genetics analysis may predict myopia in children

Genetics analysis may predict myopia in children

Laird Harrison
April 15th 2020

Preservative-free tafluprost/timolol lowers IOP well, glaucoma study shows

Preservative-free tafluprost/timolol lowers IOP well, glaucoma study shows

Laird Harrison
April 7th 2020

Ranibizumab reported safe for bilateral macular degeneration

Ranibizumab reported safe for bilateral macular degeneration

Laird Harrison
April 2nd 2020

Surgical iridotomy safer than YAG in younger uveitis patients

Surgical iridotomy safer than YAG in younger uveitis patients

Laird Harrison
April 1st 2020

Retinopathy of prematurity (ROP)

New model predicts retinopathy of prematurity based on birth characteristics

Laird Harrison
March 11th 2020

Diabetic eye disease

Topical DME drug shows promise in Phase II trial

Laird Harrison
March 10th 2020

Light-adjustable IOL technology creates novel treatment window

Light-adjustable IOL technology creates novel treatment window

Laird Harrison
October 28th 2019

Nerve growth factor promising for dry eye

Nerve growth factor promising for dry eye

Laird Harrison
May 20th 2019

Children with behavioural problems run a risk from laser pointers

Children with behavioural problems run a risk from laser pointers

Laird Harrison
May 20th 2019

Statins offer promise in ophthalmology

Statins offer promise in ophthalmology

Laird Harrison
April 1st 2019

Site Logo

Lymphopaenia may indicate sarcoidosis in uveitis

Laird Harrison
January 22nd 2019

Calcifications identified as risk factors in macular degeneration

Calcifications identified as risk factors in macular degeneration

Laird Harrison
December 13th 2018

Novel drug therapies making progress to extend wet AMD treatment

Novel drug therapies making progress to extend wet AMD treatment

Laird Harrison
November 12th 2018

Dexamethasone implant rivals anti-VEGF in real-life DMO studies

Dexamethasone implant rivals anti-VEGF in real-life DMO studies

Laird Harrison
November 2nd 2018

Site Logo

Improving access to astigmatism-correcting options during cataract surgery

Laird Harrison
October 22nd 2018

Site Logo

These approaches increase access to glaucoma therapies in developing nations

Laird Harrison
October 15th 2018

Site Logo

Acanthamoeba outbreak reported in UK contact lens wearers

Laird Harrison
October 7th 2018

Site Logo

Light mask ineffective for diabetic macular oedema

Laird Harrison
August 31st 2018

Site Logo

Study suggests education causes myopia

Laird Harrison
June 15th 2018

The more educated a person is, the more myopic they are likely to become, according to researchers at the University of Bristol, UK.

Site Logo

Genetic variants implicated in glaucoma

Laird Harrison
May 31st 2018

Site Logo

Prevalence and causes of vision loss tabulated

Laird Harrison
May 16th 2018

Site Logo

Ciclosporin A cationic emulsion promising for dry eye

Laird Harrison
May 8th 2018

Latest Updated Articles

An illustrated eyeball inside a DNA helix. Image credit: ©Adisak – stock.adobe.com
Published: February 3rd 2025 | Updated: March 4th 2025
Ocugen, Inc. receives European Medicines Agency ATMP designation for new gene therapy OCU400
A black-and-white photo of a handshake with the logos for Formycon, Klinge Biopharma, Lotus Pharmaceutical and Teva over them.
Published: January 13th 2025 | Updated: February 5th 2025
Teva partners with Klinge Biopharma, Lotus Pharmaceutical for commercialisation of Formycon’s FYB203 (biosimilar aflibercept)
A person shakes hands with a digitally-rendered arm made of light points. Image credit: ©jittawit.21 – stock.adobe.com
Published: January 31st 2024 | Updated: May 9th 2024
How biosimilars expand treatment options for patients with retinal disease
A photo showing Sebastian Rausch, PhD, clinical development manager for investigational technologies (left) and Roland Rocholz, PhD, technology and innovation manager. Image courtesy of Heidelberg Engineering
Published: July 7th 2025 | Updated: July 19th 2025
Heidelberg Engineering launches ZinserLab innovation hub, expands Orbis collaboration
European Commission grants label extension for Eylea 8 mg with extended 6-month treatment interval
Published: June 30th 2025 | Updated: July 19th 2025
European Commission grants label extension for Eylea 8 mg with extended 6-month treatment interval
A digital rendering of the earth with a digital overlay to demonstrate technology. Concept image for global impact of myopia. Image credit: ©VFX – stock.adobe.com
Published: June 25th 2025 | Updated: July 19th 2025
Myopia’s global impact, by the numbers
© 2025 MJH Life Sciences

All rights reserved.